NCCN Guidelines® Insights - B-Cell Lymphomas, Version 3.2019
These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - B-Cell Lymphomas

Diagnosis and Treatment of Diffuse Large B-Cell Lymphomas (DLBCL)

Keynote Session: Patient Experience with Innovative Therapies

The development of new and innovative cancer treatments has expanded the options available to manage patients with cancer.  However, with these advances come challenges for healthcare providers and patients.

Case 3: Immunomodulatory Drugs (IMiDs) for Relapsed/Refractory Follicular Lymphoma

You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas.  Here is your chance to earn additional CME/CE and test your knowledge.  Try your skills at this challenging case.

Case 3: Immunomodulatory Drugs (IMiDs) for Relapsed/Refractory Follicular Lymphoma

You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas.  Here is your chance to earn additional CME/CE and test your knowledge.  Try your skills at this challenging case.

CAR T-Cell Therapy: Recent Advances and Future Considerations
NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This webinar describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
Case 2: Relapsed/Refractory Mantle Cell Lymphoma

You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas.  Here is your chance to earn additional CME/CE and test your knowledge.  Try your skills at this challenging case.

Case 1: Relapsed/Refractory Low-Grade Follicular Lymphoma

You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas.  Here is your chance to earn additional CME/CE and test your knowledge.  Try your skills at this challenging case.

Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas

The goal of this program is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting

Patient Case Studies and Panel Discussion: Lymphoma

Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.

Pages

Subscribe to RSS - Non-Hodgkin's Lymphoma